WeVote
Log In

Bill

Bill

H 71

An act relating to health care entity transaction oversight and clinical decision making

2025-2026 Regular Session Introduced by Daisy Berbeco and 6 co-sponsors

H 71 would require oversight of health care entity transactions to protect clinical autonomy and patient care by scrutinizing mergers and structural changes and preserving clinicia

Read first time and referred to the Committee on Health Care
0
WeVote Research Nonpartisan
Bill Summary · H 71

Bill Overview

  • Bill: H 71
  • Session: 2025-2026
  • Jurisdiction: Vermont
  • Title: An act relating to health care entity transaction oversight and clinical decision making
  • Action to date: Read first time and referred to the Committee on Health Care (2025-01-23)
  • Primary sponsors: Woody Page; co-sponsors Mari Cordes, Brian Cina, Tiff Bluemle, Leslie Goldman, Daisy Berbeco, Alyssa Black

Purpose and Intent

H 71 aims to address two interconnected areas in Vermont’s health care system:
1. Oversight of health care entity transactions (e.g., mergers, acquisitions, or other structural changes among health care providers or systems).
2. Preservation and influence of clinical decision making within health care entities, with an emphasis on maintaining clinical independence and ensuring patient care decisions are not unduly constrained by organizational transactions or structures.

In short, the bill seeks to enhance scrutiny of large health care transactions and safeguard clinicians’ ability to make independent, patient-centered medical decisions.

Key Provisions (as described in summary since full text is not provided)

While the exact text is not provided here, typical elements of legislation with this scope often include:
- Standards for when health care entity transactions require review or approval (e.g., thresholds based on asset value, revenue, or number of covered lives).
- Creation or empowerment of a state or designated body to review proposed transactions for potential impacts on patient access, cost, quality of care, competition, and clinical autonomy.
- Criteria and processes for evaluating proposed transactions, including timelines, public notice, and opportunities for affected parties to comment.
- Requirements to maintain or protect clinical decision making, such as prohibitions or limitations on organizational mandates that could override clinicians’ professional judgment.
- Provisions for reporting, transparency, and data sharing related to health care entity transactions.
- Penalties or enforcement mechanisms for noncompliance with oversight requirements.
- Clarifications on the scope of entities covered (hospitals, health systems, physician groups, integrated delivery networks, corporate ownership, etc.).

Note: The above are typical components for health care transaction oversight and clinical decision-making safeguards. The actual bill text would specify precise definitions, thresholds, and procedural steps.

Who Would Be Affected

  • Health care entities undergoing transactions (hospitals, health systems, physician practices, and other affiliates).
  • Clinicians and medical staff whose clinical decisions could be influenced by organizational changes.
  • Patients and communities served by affected health care providers, potentially impacting access, cost, and quality of care.
  • State health department or designated oversight body responsible for evaluating transactions.
  • Public stakeholders and payers who may rely on the implications of consolidation or new organizational structures.

Procedural and Timeline Considerations

  • Initial action: Read first time and referred to the Health Care Committee, indicating the bill will move through committee review, hearings, and potential amendments.
  • Subsequent steps (typical for Vermont bills):
    • Committee hearings and vote to advance the bill.
    • Floor debate and passage by the Vermont House.
    • If passed, referral to the Senate and a similar process there (committee review, readings, and votes).
    • Potential conference committee or amendments if both chambers pass different versions.
    • Final passage and gubernatorial action (signing into law or veto).

Specific dates, deadlines, and procedural timelines would be detailed in the bill's schedule and the state legislative calendar once the bill is further advanced.

Potential Impacts and Considerations

  • Consumer and patient impact: Enhanced scrutiny could influence consolidation trends, potentially affecting access to services, pricing, and care coordination.
  • Clinical autonomy: Provisions aimed at protecting clinical decision making may reduce risk of corporate or administrative mandates compromising physician judgment.
  • Market competition: Oversight could address concerns about reduced competition, price increases, or care fragmentation stemming from large transactions.
  • Implementation burden: Health care entities may face compliance costs, data reporting requirements, and longer timelines for proposed transactions.

If you can provide the full text or specific sections of H 71, I can deliver a more precise, section-by-section summary with exact provisions, definitions, thresholds, timelines, and any fiscal impacts.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.